BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 24621081)

  • 1. Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients.
    Herbers AH; de Haan AF; van der Velden WJ; Donnelly JP; Blijlevens NM
    Transpl Infect Dis; 2014 Apr; 16(2):279-85. PubMed ID: 24621081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Febrile mucositis in haematopoietic SCT recipients.
    van der Velden WJ; Blijlevens NM; Feuth T; Donnelly JP
    Bone Marrow Transplant; 2009 Jan; 43(1):55-60. PubMed ID: 18762766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning.
    Facchini L; Martino R; Ferrari A; Piñana JL; Valcárcel D; Barba P; Granell M; Delgado J; Briones J; Sureda A; Brunet S; Sierra J
    Eur J Haematol; 2012 Jan; 88(1):46-51. PubMed ID: 22023368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteraemia coincides with low citrulline concentrations after high-dose melphalan in autologous HSCT recipients.
    Herbers AH; Blijlevens NM; Donnelly JP; de Witte TJ
    Bone Marrow Transplant; 2008 Sep; 42(5):345-9. PubMed ID: 18587437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
    Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
    Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
    Blijlevens N; Schwenkglenks M; Bacon P; D'Addio A; Einsele H; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vokurka S; Quinn B; McCann S;
    J Clin Oncol; 2008 Mar; 26(9):1519-25. PubMed ID: 18268357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
    Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective study of the digestive tract mucositis derived from myeloablative and non-myeloablative/reduced-intensity conditionings with busulfan in hematopoietic cell transplantation patient.
    Eduardo FP; Bezinelli LM; Gobbi M; Rosin FCP; Carvalho DLC; Ferreira MH; da Silva CC; Hamerschlak N; Corrêa L
    Support Care Cancer; 2019 Mar; 27(3):839-848. PubMed ID: 30109488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
    Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High incidence of graft failure in unrelated cord blood transplantation using a reduced-intensity preparative regimen consisting of fludarabine and melphalan.
    Narimatsu H; Watanabe M; Kohno A; Sugimoto K; Kuwatsuka Y; Uchida T; Murata M; Miyamura K; Morishita Y;
    Bone Marrow Transplant; 2008 Apr; 41(8):753-6. PubMed ID: 18195683
    [No Abstract]   [Full Text] [Related]  

  • 11. Icing oral mucositis: Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant.
    Chen J; Seabrook J; Fulford A; Rajakumar I
    J Oncol Pharm Pract; 2017 Mar; 23(2):116-120. PubMed ID: 26684614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral cryotherapy for oral mucositis management in patients receiving allogeneic hematopoietic stem cell transplantation: a prospective randomized study.
    Lu Y; Zhu X; Ma Q; Wang J; Jiang P; Teng S; Zhou L; Wu D; Wang H
    Support Care Cancer; 2020 Apr; 28(4):1747-1754. PubMed ID: 31302767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients.
    Vanstraelen K; Prattes J; Maertens J; Lagrou K; Schoemans H; Peersman N; Vermeersch P; Theunissen K; Mols R; Augustijns P; Annaert P; Hoenigl M; Spriet I
    Eur J Clin Pharmacol; 2016 Aug; 72(8):953-63. PubMed ID: 27066958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
    Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
    Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal damage determines the inflammatory response and early complications in patients receiving conditioning for a stem cell transplantation.
    van der Velden WJ; Herbers AH; Feuth T; Schaap NP; Donnelly JP; Blijlevens NM
    PLoS One; 2010 Dec; 5(12):e15156. PubMed ID: 21188146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence of severe oral mucositis in patients undergoing different conditioning regimens in haematopoietic stem cell transplantation.
    Nakagaki M; Kennedy GA; Gavin NC; Clavarino A; Whitfield K
    Support Care Cancer; 2022 Nov; 30(11):9141-9149. PubMed ID: 36008731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of zinc sulfate in the prevention of high-dose chemotherapy-induced mucositis: a double-blind, randomized, placebo-controlled study.
    Mansouri A; Hadjibabaie M; Iravani M; Shamshiri AR; Hayatshahi A; Javadi MR; Khoee SH; Alimoghaddam K; Ghavamzadeh A
    Hematol Oncol; 2012 Mar; 30(1):22-6. PubMed ID: 21692101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2.
    Vokurka S; Steinerova K; Karas M; Koza V
    Bone Marrow Transplant; 2009 Nov; 44(9):601-5. PubMed ID: 19349956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.
    Morabito F; Irrera G; Oliva E; Console G; Martino M; Pucci G; Messina G; Barbaro P; Palazzo S; Iacopino P
    Bone Marrow Transplant; 2001 Nov; 28(9):883-8. PubMed ID: 11781650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
    Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
    Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.